Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    1
    ...
ATC Name B/G ↓ Ingredients Dosage Form Price
N02BE01 PARAMOL G Paracetamol - 120mg/5ml 120mg/5ml Syrup, alcohol free 85,750 L.L
N02BE01 PAROL INFANTS G Paracetamol - 120mg/5ml 120mg/5ml Syrup 281,567 L.L
N02BE01 PAROL CHILDREN G Paracetamol - 240mg/5ml 240mg/5ml Elixir 314,843 L.L
N05AH03 PREXAL 5 G Olanzapine - 5mg 5mg Caplet, film coated 718,956 L.L
B02BA01 PHYTOMENADIONE (VITAMINE K1) PANPHARMA G Phytomenadione - 10mg/ml 10mg/ml Solution 740,457 L.L
N02BE01 PARACETAMOL PANPHARMA G Paracetamol - 10mg/ml 10mg/ml Injectable solution 1,959,322 L.L
N06BA09 PMS-ATOMOXETINE G Atomoxetine (HCl) - 60mg 60mg Capsule 5,228,891 L.L
G04BX14 PRIXETIN 30 G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 2,105,353 L.L
N02BE01 PARACETAMOL S.A.L.F G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 5,542,006 L.L
N06BA09 PMS-ATOMOXETINE G Atomoxetine (HCl) - 40mg 40mg Capsule 4,706,136 L.L
G04BX14 PRIXETIN 60 G Dapoxetine (hydrochloride) - 60mg Tablet, film coated 1,479,123 L.L
M02AA07 PIROXICALM G Piroxicam - 0.5% 0.5% Gel 207,336 L.L
N02BE01 PARACETAMOL B.BRAUN G Paracetamol - 1000mg/100ml 1000mg/100ml Injectable solution 129,009 L.L
N05AH03 PRANZA G Olanzapine - 5mg 5mg Tablet, orodispersible 1,773,872 L.L
N02BE01 PARACETAMOL MACOPHARMA G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 9,350,840 L.L
N06BA09 PMS-ATOMOXETINE G Atomoxetine (HCl) - 25mg 25mg Capsule 4,121,565 L.L
N02BE01 PARACETAMOL NORMON G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 9,633,134 L.L
N06BA09 PMS-ATOMOXETINE G Atomoxetine (HCl) - 18mg 18mg Capsule 3,744,073 L.L
N02BE01 PARACETAMOL PANPHARMA G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 8,675,675 L.L
C10AA07 PMS-ROSUVASTATIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 564,414 L.L
N02BE01 PARACETAMOL PANPHARMA G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 2,215,996 L.L
C04AD03 PENTOXIFYLLINE SR G Pentoxifylline - 1160 400mg Tablet, sustained release 1,478,227 L.L
C10AA07 PREVAST 10-IPS G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 575,933 L.L
G04CA01 PROSTETROL G Alfuzosin HCl - 10mg 10mg Tablet, modified release 360,150 L.L
N02BE01 PARAMED G Paracetamol - 10mg/ml 10mg/ml Injectable solution 814,369 L.L
G04CA01 PROSTETROL G Alfuzosin HCl - 10mg 10mg Tablet, modified release 682,672 L.L
S01EC03 PROGLAU G Dorzolamide HCl - 20mg/ml 20mg/ml Drops solution 517,379 L.L
G04CA02 PROSTAFINE G Tamsulosin HCl - 0.4mg 0.4mg Capsule, modified release 761,511 L.L
N02BE01 PARACEROL G Paracetamol - 10mg/ml 10mg/ml Injectable solution 1,536,012 L.L
N05AH03 PRANZA G Olanzapine - 10mg 10mg Tablet, orodispersible 3,553,120 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025